MCID: ADR004
MIFTS: 39

Adrenal Cortical Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Adenocarcinoma

MalaCards integrated aliases for Adrenal Cortical Adenocarcinoma:

Name: Adrenal Cortical Adenocarcinoma 12 15
Adrenal Cortex Adenocarcinoma 12
Adrenocortical Carcinoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3959
UMLS 71 C0206686

Summaries for Adrenal Cortical Adenocarcinoma

Disease Ontology : 12 An adrenocortical carcinoma that originates in the cortex of the adrenal gland and derives from epithelial cells of glandular origin.

MalaCards based summary : Adrenal Cortical Adenocarcinoma, also known as adrenal cortex adenocarcinoma, is related to legius syndrome and adrenal carcinoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Cortical Adenocarcinoma is SPRY2 (Sprouty RTK Signaling Antagonist 2), and among its related pathways/superpathways are Development HGF signaling pathway and Development Dopamine D2 receptor transactivation of EGFR. The drugs Bromocriptine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related phenotype is Increased viability with nutlin-3.

Related Diseases for Adrenal Cortical Adenocarcinoma

Diseases related to Adrenal Cortical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 legius syndrome 10.0 SPRY2 SPRY1
2 adrenal carcinoma 9.9
3 adenocarcinoma 9.9
4 dyskeratosis congenita, autosomal dominant 3 9.8 RPS6KA6 RPS6KA1
5 birk-barel syndrome 9.7 KCNK9 KCNK13
6 coffin-lowry syndrome 9.6 RPS6KA6 RPS6KA1

Graphical network of the top 20 diseases related to Adrenal Cortical Adenocarcinoma:



Diseases related to Adrenal Cortical Adenocarcinoma

Symptoms & Phenotypes for Adrenal Cortical Adenocarcinoma

UMLS symptoms related to Adrenal Cortical Adenocarcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with nutlin-3 GR00123-A 8.62 BAD KCNK9

Drugs & Therapeutics for Adrenal Cortical Adenocarcinoma

Drugs for Adrenal Cortical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3 Hormones Phase 4
4 Hormone Antagonists Phase 4
5 Dopamine agonists Phase 4
6 Dopamine Agents Phase 4
7 Neurotransmitter Agents Phase 4
8 Antiparkinson Agents Phase 4
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
11
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Mitotane Approved Phase 3 53-19-0 4211
14
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
15
Etoposide Approved Phase 3 33419-42-0 36462
16 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
17 Anti-Bacterial Agents Phase 3
18 Cola Phase 3
19 Liver Extracts Phase 3
20
Liposomal doxorubicin Phase 3 31703
21 Antibiotics, Antitubercular Phase 3
22 Anesthetics Phase 3
23 Narcotics Phase 3
24 Analgesics Phase 3
25 Analgesics, Opioid Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Tubulin Modulators Phase 3
29 Antimitotic Agents Phase 3
30 Antineoplastic Agents, Hormonal Phase 3
31 Etoposide phosphate Phase 3
32 Dermatologic Agents Phase 3
33 Keratolytic Agents Phase 3
34 Podophyllotoxin Phase 3 518-28-5
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
37
Indinavir Approved Phase 2 150378-17-9 5362440
38
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
39
Lactitol Approved, Investigational Phase 2 585-88-6, 585-86-4 493591
40
acetic acid Approved Phase 2 64-19-7 176
41
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
42
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
43
Sodium citrate Approved, Investigational Phase 2 68-04-2
44
Tamoxifen Approved Phase 2 10540-29-1 2733526
45
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
46
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
47
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
48
Pembrolizumab Approved Phase 2 1374853-91-4
49
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
50
Ipilimumab Approved Phase 2 477202-00-9

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
2 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Unknown status NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
3 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
4 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Recruiting NCT00777244 Phase 3 MITOTANE
7 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
9 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
10 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
12 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
13 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
14 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
15 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
16 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
17 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
18 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
19 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
20 An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201) Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
21 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
22 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
23 Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
24 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
25 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
26 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
27 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
28 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
29 Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
30 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
31 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
32 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
33 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
34 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
35 MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study Recruiting NCT02007148 Phase 2 capecitabine;Docetaxel
36 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
37 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
38 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
39 An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome Enrolling by invitation NCT03604198 Phase 2 relacorilant
40 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04187404 Phase 1, Phase 2
41 Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Not yet recruiting NCT04318730 Phase 2 Camrelizumab
42 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Not yet recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
43 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
44 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
45 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
47 A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. Withdrawn NCT00469469 Phase 2 Bevacizumab
48 Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
49 A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
50 A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications Completed NCT01772004 Phase 1 Avelumab

Search NIH Clinical Center for Adrenal Cortical Adenocarcinoma

Genetic Tests for Adrenal Cortical Adenocarcinoma

Anatomical Context for Adrenal Cortical Adenocarcinoma

MalaCards organs/tissues related to Adrenal Cortical Adenocarcinoma:

40
Cortex, Adrenal Gland, Adrenal Cortex, Liver, Testes, Lung, Thyroid

Publications for Adrenal Cortical Adenocarcinoma

Articles related to Adrenal Cortical Adenocarcinoma:

(show top 50) (show all 2514)
# Title Authors PMID Year
1
Surgical Approach to Abdominal Tumors Involving the Inferior Vena Cava. 61
32558442 2020
2
Report of 2 Pediatric Cases With Li-Fraumeni Syndrome Related Malignancy in a Family. 61
32555031 2020
3
Update on in-vivo preclinical research models in adrenocortical carcinoma. 61
32304391 2020
4
Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. 61
32561853 2020
5
Characteristics of adrenocortical carcinoma in South Korea: a registry-based nationwide survey. 61
32438344 2020
6
A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma. 61
32483162 2020
7
Development and validation of prognostic nomograms in patients with adrenocortical carcinoma: a population-based study. 61
32072388 2020
8
Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma. 61
32089260 2020
9
Four cypermethrin isomers induced stereoselective metabolism in H295R cells. 61
32573024 2020
10
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC. 61
32276262 2020
11
A Modern Assessment of Cancer Risk in Adrenal Incidentalomas: Analysis of 2219 Patients. 61
32541223 2020
12
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. 61
32524319 2020
13
Two subsequent metachroneus solid tumors: Oncocytic variant adrenocortical carcinoma and rhabdomyosarcoma of childhood: Case report and Literature Review. 61
32539319 2020
14
Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma. 61
32522271 2020
15
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. 61
31441020 2020
16
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria. 61
32481732 2020
17
The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. 61
32468513 2020
18
Sustained remission of Lynch syndrome-associated metastatic adrenocortical carcinoma following checkpoint inhibitor therapy-associated multiorgan autoimmunity. 61
32449531 2020
19
Patient and Partner Perspectives on Health-Related Quality of Life in Adrenocortical Carcinoma. 61
32342024 2020
20
Metastatic Adrenocortical Carcinoma Causing Profound Right Ventricular Outflow Tract Obstruction: An Improvement Following Surgical Resection. 61
32370618 2020
21
Copper affects steroidogenesis and viability of human adrenocortical carcinoma (NCI-H295R) cell line in vitro. 61
32437254 2020
22
Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study. 61
32449514 2020
23
Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. 61
32474412 2020
24
[Diffuse retinal pigment epitheliopathy secondary to adrenocortical carcinoma]. 61
32241589 2020
25
Past, Present and Future of Epigenetics in Adrenocortical Carcinoma. 61
32414074 2020
26
Open vs laparoscopic adrenalectomy for localized adrenocortical carcinoma. 61
32421867 2020
27
Adrenocortical tumorigenesis: Lessons from genetics. 61
32507359 2020
28
Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study. 61
32451468 2020
29
Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. 61
31900481 2020
30
Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. 61
32448148 2020
31
HORMONALLY FUNCTIONING ECTOPIC ADRENOCORTICAL CARCINOMA. 61
32339030 2020
32
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. 61
32260362 2020
33
Minimally Invasive Versus Open Adrenalectomy in Patients with Adrenocortical Carcinoma: A Meta-analysis. 61
32277316 2020
34
ASO Author Reflections: Minimally Invasive Versus Open Adrenalectomy in Patients with Adrenocortical Carcinoma: A Meta-analysis. 61
32277318 2020
35
Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. 61
32303972 2020
36
A rare case of oncocytic adrenocortical carcinoma clinically presented as an incidentaloma. 61
32249250 2020
37
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells. 61
32283844 2020
38
Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study. 61
32295220 2020
39
Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. 61
31241762 2020
40
The outcome of childhood adrenocortical carcinoma in Egypt: A model from developing countries. 61
31971470 2020
41
Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant. 61
32088909 2020
42
A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. 61
32147670 2020
43
Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis. 61
32147961 2020
44
Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. 61
31941752 2020
45
Steroidogenesis in the NCI-H295 Cell Line Model is Strongly Affected By Culture Conditions and Substrain. 61
32349159 2020
46
Primary adrenal leiomyosarcoma: A case report. 61
32190312 2020
47
Phytochemical analysis and biological activities of in vitro cultured Nidularium procerum, a bromeliad vulnerable to extinction. 61
32332902 2020
48
Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. 61
31894378 2020
49
Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations. 61
32282928 2020
50
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 61
32290298 2020

Variations for Adrenal Cortical Adenocarcinoma

Expression for Adrenal Cortical Adenocarcinoma

Search GEO for disease gene expression data for Adrenal Cortical Adenocarcinoma.

Pathways for Adrenal Cortical Adenocarcinoma

Pathways related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.25 SH3KBP1 RPS6KA6 RPS6KA1 BAD
2
Show member pathways
12.24 RPS6KA6 RPS6KA1 BAD
3
Show member pathways
12.21 RPS6KA6 RPS6KA1 KCNK9 KCNK7 KCNK13
4
Show member pathways
12.01 RPS6KA6 RPS6KA1 BAD
5
Show member pathways
11.88 RPS6KA6 RPS6KA1 BAD
6 11.85 SPRY2 SH3KBP1 RPS6KA1
7 11.75 SPRY2 SPRY1 SH3KBP1
8
Show member pathways
11.72 RPS6KA6 RPS6KA1 BAD
9
Show member pathways
11.71 KCNK9 KCNK7 KCNK13
10
Show member pathways
11.53 KCNK9 KCNK7 KCNK13
11
Show member pathways
11.3 SPRY2 SPRY1 SH3KBP1
12 11.21 SPRY2 RPS6KA1
13 11.14 RPS6KA6 RPS6KA1
14 11.04 SPRY2 SH3KBP1
15 10.98 SPRY2 SPRY1 RPS6KA1 BAD

GO Terms for Adrenal Cortical Adenocarcinoma

Biological processes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 potassium ion transport GO:0006813 9.61 KCNK9 KCNK7 KCNK13
2 potassium ion transmembrane transport GO:0071805 9.58 KCNK9 KCNK7 KCNK13
3 negative regulation of GTPase activity GO:0034260 9.56 SPRY2 SPRY1
4 regulation of signal transduction GO:0009966 9.55 SPRY2 SPRY1
5 negative regulation of MAP kinase activity GO:0043407 9.54 SPRY2 SPRY1
6 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.54 SPRY2 SPRY1 RPS6KA6
7 negative regulation of epithelial to mesenchymal transition GO:0010719 9.52 SPRY2 SPRY1
8 establishment of mitotic spindle orientation GO:0000132 9.51 SPRY2 SPRY1
9 negative regulation of Ras protein signal transduction GO:0046580 9.49 SPRY2 SPRY1
10 animal organ development GO:0048513 9.48 SPRY2 SPRY1
11 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.46 SPRY2 SPRY1
12 bud elongation involved in lung branching GO:0060449 9.32 SPRY2 SPRY1
13 negative regulation of lens fiber cell differentiation GO:1902747 9.26 SPRY2 SPRY1
14 negative regulation of neurotrophin TRK receptor signaling pathway GO:0051387 9.16 SPRY2 SPRY1
15 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.13 SPRY2 SPRY1 SH3KBP1
16 stabilization of membrane potential GO:0030322 8.8 KCNK9 KCNK7 KCNK13

Molecular functions related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium channel activity GO:0005267 9.33 KCNK9 KCNK7 KCNK13
2 ribosomal protein S6 kinase activity GO:0004711 8.96 RPS6KA6 RPS6KA1
3 potassium ion leak channel activity GO:0022841 8.8 KCNK9 KCNK7 KCNK13

Sources for Adrenal Cortical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....